Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixazomib - Takeda Oncology

Drug Profile

Ixazomib - Takeda Oncology

Alternative Names: Ixazomib citrate; MLN-2238; MLN-9708; NINLARO

Latest Information Update: 02 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Millennium Pharmaceuticals; University of California, San Diego
  • Developer Celgene Corporation; Helsinki University Central Hospital; HOVON Foundation; Massachusetts General Hospital; National Cancer Institute (USA); Northside Hospital; Northwestern University; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Amides; Antineoplastics; Antivirals; Chlorobenzenes; Organic boron compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase III Amyloid light-chain amyloidosis
  • Phase II Acute myeloid leukaemia; Amyloidosis; Follicular lymphoma; Graft-versus-host disease; Haematological malignancies; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I/II HIV infections
  • No development reported Lupus nephritis; Non-small cell lung cancer; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Bladder cancer; Solid tumours

Most Recent Events

  • 29 Nov 2023 Millennium Pharmaceuticals and Takeda completes a phase-III clinical trials in Multiple myeloma (Newly diagnosed, Second-line therapy or greater) in China, Germany, Belgium, Czech Republic, Austria, Portugal, Denmark, Spain, Sweden, Hungary, France, Greece, Croatia, Poland, Italy (PO) (NCT03748953) (EudraCt2014-001394-13)
  • 31 Oct 2023 Takeda completes a phase I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in the USA (NCT02206425)
  • 19 Oct 2023 Takeda terminates a phase II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater, Newly diagnosed, Maintenance therapy) in USA (PO) due to insufficient enrollment (NCT03733691)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top